To the full analysis
SK Biopharmaceuticals stock: growth
326030.KSSK Biopharmaceuticals reported $529.75M in revenue for fiscal 2025, up 29.1% on the prior year, up 93.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
23.3%
per year from 2011 to 2025, per share 17.5%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2011 | |
|---|---|---|---|
| Revenue | 93.6% | 25.8% | 23.3% |
| Revenue per share | 90.2% | 20.2% | 17.5% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2011 | $28.21M | −$14.59M | −$13.89M |
| 2012 | $38.83M | −$22.73M | −$18.96M |
| 2013 | $45.31M | −$30.73M | −$32.93M |
| 2014 | $54.3M | −$27.77M | −$32.39M |
| 2015 | $53.53M | −$21.03M | −$24.4M |
| 2016 | $67.41M | −$22.76M | −$43.28M |
| 2017 | $63.95M | −$73.19M | −$74.95M |
| 2018 | $823.58K | −$103.51M | −$106.98M |
| 2019 | $92.84M | −$53.61M | −$71.5M |
| 2020 | $19.49M | −$185.45M | −$168.7M |
| 2021 | $313.8M | $48.61M | −$74.1M |
| 2022 | $184.53M | −$104.51M | −$124.34M |
| 2023 | $266.02M | −$24.65M | −$73.05M |
| 2024 | $410.46M | $180.45M | $61.07M |
| 2025 | $529.75M | $200.1M | $130.16M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₩1,334.10)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 12 Dec 2025)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.